UTHR
$167.18
United Therapeutic
($1.62)
(.96%)
UTHR
Earnings Whisper ®
N/A
1st Quarter March 2021
Consensus:  $3.10
Revenue:  $361.08 Mil
Wednesday
May 26
6:00 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when UTHR reports earnings?
Beat
Meet
Miss

Where is UTHR's stock price going from here?
Up
Flat
Down
Stock chart of UTHR
Analysts
Summary of analysts' recommendations for UTHR
Score
Grade
Pivots
Resistance
$173.90
$172.08
$169.63

$167.81

Support
$165.36
$163.54
$161.09
Tweet
Growth
Description
United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of innovative products to address the unmet medical needs of patients with chronic and life-threatening conditions. United Therapeutics (UT) has an overarching commitment to environmental sustainability. The company's product candidates include Adcirca is a phosphodiesterase 5 (PDE-5) inhibitor indicated for the treatment of pulmonary arterial hypertension (PAH)(WHO Group 1) to improve exercise ability in PAH patients. Orenitram is a prostacyclin vasodilator indicated for treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise capacity. Remodulin is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) to diminish symptoms associated with exercise. Tyvaso is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability.
Peers
InterCeptVertex PharmaceuticalsRegeneron PharmaceuticalsBioMarin PharmaceuticalBristol-Myers SquibbPfizerZoetisMerck & Co.Johnson & JohnsonUltragenyx Pharmaceutical